Vol 11, Supplement 1 (January 25, 2019): Journal of Thoracic Disease (Advances in Theranostic Biomarkers for Lung Cancer: from Clinical to Molecular Pathology)

Review Article

Advance of theragnosis biomarkers in lung cancer: from clinical to molecular pathology and biology
Christina Alidousty, Till Baar, Carina Heydt, Svenja Wagener-Ryczek, Anna Kron, Juergen Wolf, Reinhard Buettner, Anne Maria Schultheis
Mesenchymal tumors of the lung: diagnostic pathology, molecular pathogenesis, and identified biomarkers
Hirotsugu Hashimoto, Yuta Tsugeno, Keisuke Sugita, Kentaro Inamura
Molecular markers and prediction of response to immunotherapy in non-small cell lung cancer, an update
Hélène Blons, Simon Garinet, Pierre Laurent-Puig, Jean-Baptiste Oudart
Gross handling of pulmonary resection specimen: maintaining the 3-dimensional orientation
Teodora Radonic, Chris Dickhoff, Mari Mino-Kenudson, Rutger Lely, Rick Paul, Erik Thunnissen
Circulating tumor cells (CTCs) for the noninvasive monitoring and personalization of non-small cell lung cancer (NSCLC) therapies
Patrycja Pawlikowska, Vincent Faugeroux, Marianne Oulhen, Agathe Aberlenc, Tala Tayoun, Emma Pailler, Françoise Farace
The challenges of evaluating predictive biomarkers using small biopsy tissue samples and liquid biopsies from non-small cell lung cancer patients
Paul Hofman
Resistances to EGFR tyrosine kinase inhibitors in lung cancer— how to routinely track them in a molecular pathology laboratory?
Véronique Hofman, Paul Hofman
Current views on tumor mutational burden in patients with nonsmall cell lung cancer treated by immune checkpoint inhibitors
Léa Berland, Simon Heeke, Olivier Humbert, Adam Macocco, Elodie Long-Mira, Sandra Lassalle, Virginie Lespinet-Fabre, Salomé Lalvée, Olivier Bordone, Charlotte Cohen, Sylvie Leroy, Véronique Hofman, Paul Hofman, Marius Ilié
Update on emerging biomarkers in lung cancer
Eric H. Bernicker, Timothy Craig Allen, Phillip T. Cagle
Programmed death ligand 1 immunohistochemistry in non-small cell lung carcinoma
Sylvie Lantuejoul, Diane Damotte, Véronique Hofman, Julien Adam
Are there any theranostic biomarkers in small cell lung carcinoma?
Federica Pezzuto, Francesco Fortarezza, Francesca Lunardi, Fiorella Calabrese
Circulating free tumor DNA in non-small cell lung cancer (NSCLC): clinical application and future perspectives
Guillaume Herbreteau, Audrey Vallée, Sandrine Charpentier, Nicola Normanno, Paul Hofman, Marc G. Denis

The supplement “Advances in Theranostic Biomarkers for Lung Cancer: from Clinical to Molecular Pathology” was commissioned by the Editorial office, Journal of Thoracic Disease without any sponsorship or funding. Paul Hofman served as the unpaid Guest Editor for the supplement.